Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, has raised HK$7.70 billion (US$981 million) through a sale of additional shares in Hong Kong as it rides the wave of bullish appetite for Chinese biotechnology shares. The Shanghai-based company sold 73.8 million new shares to institutional investors at HK$104.27 each, a 6.9 per cent discount…
Wuxi AppTec, Asia’s largest provider of contract pharmaceutical research, has raised HK$7.70 billion (US$981 million) through a sale of additional shares in Hong Kong as it rides the wave of bullish appetite for Chinese biotechnology shares. The Shanghai-based company sold 73.8 million new shares to institutional investors at HK$104.27 each, a 6.9 per cent discount…
Plus, news about Rivus and Crown Labs: Two Chinese biotechs file for stock listings in Hong Kong: Shanghai Bao Pharmaceuticals and Sichuan Biokin Pharmaceutical join … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. Source link
There’s been something of a sea change in the economic outlook for 2025, in the aftermath of last month’s election. The prospect of a second Trump administration, with his known preference for deregulation and tax cuts, has market watchers expecting a growth-friendly environment. Desh Peramunetilleke, Jefferies’ Global Head of Quantitative Strategy, notes that reduced regulation,…